| Year |
Citation |
Score |
| 2024 |
Li JZ, Melberg M, Kittilson A, Abdel-Mohsen M, Li Y, Aga E, Bosch RJ, Wonderlich ER, Kinslow J, Giron LB, Di Germanio C, Pilkinton M, MacLaren L, Keefer M, Fox L, ... ... Acosta E, et al. Predictors of HIV rebound differ by timing of antiretroviral therapy initiation. Jci Insight. 9. PMID 38329130 DOI: 10.1172/jci.insight.173864 |
0.317 |
|
| 2023 |
Chandasana H, Thapar M, Hayes S, Baker M, Gibb DM, Turkova A, Ford D, Ruel T, Wiznia A, Fairlie L, Bwakura-Dangarembizi M, Mujuru H, Alvero C, Farhad M, Hazra R, ... ... Acosta EP, et al. Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents. Clinical Pharmacokinetics. PMID 37603217 DOI: 10.1007/s40262-023-01289-5 |
0.335 |
|
| 2023 |
Brooks KM, Kiser JJ, Ziemba L, Ward S, Rani Y, Cressey TR, Masheto GR, Cassim H, Deville JG, Ponatshego PL, Patel F, Aurpibul L, Barnabas SL, Mustich I, Coletti A, ... ... Acosta EP, et al. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. The Lancet. Hiv. 10: e506-e517. PMID 37541705 DOI: 10.1016/S2352-3018(23)00107-8 |
0.303 |
|
| 2021 |
McMahon DK, Zheng L, Cyktor JC, Aga E, Macatangay BJ, Godfrey C, Para M, Mitsuyasu RT, Hesselgesser J, Dragavon J, Dobrowolski C, Karn J, Acosta EP, Gandhi RT, Mellors JW. A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy. The Journal of Infectious Diseases. 224: 648-656. PMID 34398236 DOI: 10.1093/infdis/jiaa777 |
0.315 |
|
| 2020 |
McMahon DK, Zheng L, Cyktor JC, Aga E, Macatangay BJ, Godfrey C, Para M, Mitsuyasu RT, Hesselgesser J, Dragavon J, Dobrowolski C, Karn J, Acosta EP, Gandhi RT, Mellors JW, et al. A phase I/II randomized, placebo-controlled trial of romidepsin in persons with HIV-1 on suppressive antiretroviral therapy to assess safety and activation of HIV-1 expression (A5315). The Journal of Infectious Diseases. PMID 33349862 DOI: 10.1093/infdis/jiaa777 |
0.31 |
|
| 2020 |
Clarke DF, Lommerse J, Acosta EP, Cababasay MP, Wang J, Spector SA, Chain A, Smith E, Teppler H, Hazra R, Calabrese K, Graham B, Popson S, Bryson Y, Mirochnick M, et al. IMPACT OF LOW BIRTH WEIGHT AND PREMATURITY ON NEONATAL RALTEGRAVIR PHARMACOKINETICS: IMPAACT P1097. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 32925360 DOI: 10.1097/Qai.0000000000002492 |
0.375 |
|
| 2020 |
Krogstad P, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Brown E, Denson K, Graham B, Hovind L, Sise T, Teppler H, Mathiba SR, Fairlie L, Winckler JL, et al. Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis. Journal of the Pediatric Infectious Diseases Society. PMID 32448902 DOI: 10.1093/Jpids/Piaa039 |
0.388 |
|
| 2020 |
Bull M, Mitchell C, Soria J, Styrchak S, Williams C, Dragavon J, Ryan KJ, Acosta E, Onchiri F, Coombs RW, La Rosa A, Ticona E, Frenkel LM. Genital shedding of human immunodeficiency virus type-1 (HIV) when antiretroviral therapy (ART) suppresses HIV replication in the plasma. The Journal of Infectious Diseases. PMID 32274499 DOI: 10.1093/Infdis/Jiaa169 |
0.433 |
|
| 2020 |
Acosta E, Bowlin T, Brooks J, Chiang L, Hussein I, Kimberlin D, Kauvar LM, Leavitt R, Prichard M, Whitley R. Advances in the Development of Therapeutics for Cytomegalovirus Infections. The Journal of Infectious Diseases. 221: S32-S44. PMID 32134483 DOI: 10.1093/Infdis/Jiz493 |
0.382 |
|
| 2020 |
Guimbellot JS, Ryan KJ, Anderson JD, Liu Z, Kersh L, Esther CR, Rowe SM, Acosta EP. Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 32044246 DOI: 10.1016/J.Jcf.2020.01.011 |
0.341 |
|
| 2020 |
Devanand DP, Andrews H, Kreisl WC, Razlighi Q, Gershon A, Stern Y, Mintz A, Wisniewski T, Acosta E, Pollina J, Katsikoumbas M, Bell KL, Pelton GH, Deliyannides D, Prasad KM, et al. Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial. Bmj Open. 10: e032112. PMID 32034019 DOI: 10.1136/Bmjopen-2019-032112 |
0.317 |
|
| 2020 |
Clarke DF, Acosta EP, Cababasay M, Wang J, Chain A, Teppler H, Popson S, Graham B, Smith B, Hazra R, Calabrese K, Bryson Y, Spector SA, Lommerse J, Mirochnick M, et al. Raltegravir (RAL) in neonates: Dosing, pharmacokinetics (PK), and safety in HIV-1 exposed neonates at risk of infection (IMPAACT P1110). Journal of Acquired Immune Deficiency Syndromes (1999). PMID 31913995 DOI: 10.1097/Qai.0000000000002294 |
0.445 |
|
| 2019 |
Meyers T, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Marillo L, Denson K, Hovind L, Sise T, Teppler H, Mathiba SR, Masenya M, Hesseling A, Cotton MF, et al. Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. Aids (London, England). 33: 2197-2203. PMID 31689263 DOI: 10.1097/Qad.0000000000002369 |
0.424 |
|
| 2019 |
Johnson VA, Cramer YS, Rosenkranz SL, Becker S, Klingman KL, Kallungal B, Coakley E, Acosta EP, Calandra G, Saag M. Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group (ACTG) Protocol A5210. Aids Research and Human Retroviruses. PMID 31099252 DOI: 10.1089/Aid.2018.0256 |
0.46 |
|
| 2019 |
Viani RM, Ruel T, Alvero C, Fenton T, Acosta EP, Hazra R, Townley E, Palumbo P, Buchanan AM, Vavro C, Singh R, Graham B, Anthony P, George K, Wiznia A, et al. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study. Journal of the Pediatric Infectious Diseases Society. PMID 30951600 DOI: 10.1093/Jpids/Piy139 |
0.308 |
|
| 2019 |
Nyaku AN, Zheng L, Gulick RM, Olefsky M, Berzins B, Wallis CL, Godfrey C, Sax PE, Acosta EP, Haas DW, Smith KY, Sha BE, Van Dam CN, Taiwo BO. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353. The Journal of Antimicrobial Chemotherapy. PMID 30668695 DOI: 10.1093/Jac/Dky564 |
0.44 |
|
| 2019 |
Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD. Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202. Antimicrobial Agents and Chemotherapy. PMID 30642925 DOI: 10.1128/Aac.01638-18 |
0.408 |
|
| 2018 |
Nachman S, Alvero C, Teppler H, Homony B, Rodgers AJ, Graham BL, Fenton T, Frenkel LM, Browning RS, Hazra R, Wiznia AA, Acosta E, Douglas S, Fry C, Kuryla S, et al. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial. The Lancet Hiv. 5. PMID 30527329 DOI: 10.1016/S2352-3018(18)30257-1 |
0.464 |
|
| 2018 |
Momper JD, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Badell ML, Acosta EP, Purswani M, Smith E, Chakhtoura N, Park K, Burchett S, Shapiro DE, Mirochnick M, et al. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. Aids (London, England). PMID 30134297 DOI: 10.1097/Qad.0000000000001992 |
0.338 |
|
| 2018 |
Namazi G, Fajnzylber JM, Aga E, Bosch R, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, et al. The Control of HIV after Antiretroviral Medication Pause (CHAMP) study: post-treatment controllers identified from 14 clinical studies. The Journal of Infectious Diseases. PMID 30085241 DOI: 10.1093/Infdis/Jiy479 |
0.391 |
|
| 2018 |
Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL, Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT, Jacobson JM, et al. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. The Journal of Clinical Investigation. PMID 30024859 DOI: 10.1172/Jci120549 |
0.393 |
|
| 2018 |
Lahiri CD, Brown NL, Ryan KJ, Acosta EP, Sheth AN, Mehta CC, Ingersoll J, Ofotokun I. HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy. Aids (London, England). PMID 30005011 DOI: 10.1097/Qad.0000000000001945 |
0.405 |
|
| 2018 |
Bull ME, Mitchell C, Soria J, Styrchak S, Williams-Wietzikoski C, Legard J, Mckernan-Mullin J, Kraft K, Onchiri F, Stern J, Holte S, Ryan KJ, Acosta EP, La Rosa A, Coombs RW, et al. Monotypic low-level HIV viremias during ART are associated with disproportionate production of X4 virions and systemic immune activation. Aids (London, England). PMID 29683841 DOI: 10.1097/Qad.0000000000001824 |
0.387 |
|
| 2018 |
Guimbellot JS, Acosta EP, Rowe SM. Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatric Pulmonology. PMID 29488691 DOI: 10.1002/Ppul.23971 |
0.31 |
|
| 2018 |
Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Buschur SL, Acosta EP, Smith E, Chakhtoura N, Burchett S, Mirochnick M. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. Aids (London, England). PMID 29369162 DOI: 10.1097/Qad.0000000000001755 |
0.339 |
|
| 2017 |
Taiwo BO, Marconi VC, Berzins B, Moser CB, Nyaku AN, Fichtenbaum CJ, Benson CA, Wilkin T, Koletar SL, Colasanti J, Acosta EP, Li JZ, Sax PE. Dolutegravir plus lamivudine maintain HIV-1 suppression through week 48 in a pilot randomized trial. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 29293895 DOI: 10.1093/Cid/Cix1131 |
0.446 |
|
| 2017 |
Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E, Haas D, Smith KY, Sha B, Van Dam C, Gulick RM. ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 29253097 DOI: 10.1093/Cid/Cix1083 |
0.417 |
|
| 2017 |
Xu F, Acosta EP, Liang L, He Y, Yang J, Kerstner-Wood C, Zheng Q, Huang J, Wang K. Current status of the Pharmacokinetics and Pharmacodynamics of HIV-1 Entry Inhibitors and HIV Therapy. Current Drug Metabolism. PMID 28738768 DOI: 10.2174/1389200218666170724112412 |
0.474 |
|
| 2017 |
Barbian HJ, Jackson-Jewett R, Brown CS, Bibollet-Ruche F, Learn GH, Decker T, Kreider EF, Li Y, Denny TN, Sharp PM, Shaw GM, Lifson J, Acosta EP, Saag MS, Bar KJ, et al. Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee. Retrovirology. 14: 35. PMID 28576126 DOI: 10.1186/S12977-017-0359-0 |
0.387 |
|
| 2017 |
Gay CL, Bosch RJ, Ritz J, Hataye JM, Aga E, Tressler RL, Mason SW, Hwang CK, Grasela DM, Ray N, Cyktor JC, Coffin JM, Acosta EP, Koup RA, Mellors JW, et al. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. The Journal of Infectious Diseases. PMID 28431010 DOI: 10.1093/Infdis/Jix191 |
0.364 |
|
| 2017 |
McMahon D, Zheng L, Cyktor J, Aga E, Macatangay BJ, Godfrey C, Para M, Mitsuyasu R, Hogg E, Hesselgesser J, Acosta E, Gandhi RT, Mellors JW. Single romidepsin infusions do not increase HIV expression in persons on ART (A5315) Journal of Virus Eradication. 3: 41-42. DOI: 10.1016/S2055-6640(20)30557-4 |
0.352 |
|
| 2016 |
Cressey TR, Hazra R, Wiznia A, Foca M, Jean-Philippe P, Graham B, King JR, Britto P, Carey VJ, Acosta EP, Yogev R. Pharmacokinetics of Unboosted Atazanavir in Treatment-Experienced HIV-infected Children, Adolescents and Young Adults. The Pediatric Infectious Disease Journal. PMID 27583590 DOI: 10.1097/Inf.0000000000001320 |
0.442 |
|
| 2016 |
Foca M, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Britto P, Carey VJ, King J, Acosta EP, Cressey TR. Rilpivirine Pharmacokinetics Without and With Darunavir/ritonavir once daily in Adolescents and Young Adults. The Pediatric Infectious Disease Journal. PMID 27187753 DOI: 10.1097/Inf.0000000000001214 |
0.334 |
|
| 2016 |
Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Fletcher CV, Acosta EP. Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults. Journal of the Pediatric Infectious Diseases Society. PMID 27103489 DOI: 10.1093/Jpids/Piw017 |
0.549 |
|
| 2015 |
Nachman S, Alvero C, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Rizk ML, Spector SA, Frenkel LM, Worrell C, Handelsman E, Wiznia A. Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age. Journal of the Pediatric Infectious Diseases Society. 4: e76-83. PMID 26582887 DOI: 10.1093/Jpids/Piu146 |
0.408 |
|
| 2015 |
Abzug MJ, Michaels MG, Wald E, Jacobs RF, Romero JR, Sánchez PJ, Wilson G, Krogstad P, Storch GA, Lawrence R, Shelton M, Palmer A, Robinson J, Dennehy P, Sood SK, ... ... Acosta EP, et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis. Journal of the Pediatric Infectious Diseases Society. PMID 26407253 DOI: 10.1093/Jpids/Piv015 |
0.304 |
|
| 2015 |
Lahiri CD, Reed-Walker K, Sheth AN, Acosta EP, Vunnava A, Ofotokun I. Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimens. Journal of Clinical Pharmacology. PMID 26247878 DOI: 10.1002/Jcph.612 |
0.424 |
|
| 2015 |
Viani RM, Alvero C, Fenton T, Acosta EP, Hazra R, Townley E, Steimers D, Min S, Wiznia A. Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-Experienced HIV-1 Infected Adolescents: 48-Week Results from IMPAACT P1093. The Pediatric Infectious Disease Journal. PMID 26244832 DOI: 10.1097/Inf.0000000000000848 |
0.459 |
|
| 2015 |
Wanga V, Venuto C, Morse GD, Acosta EP, Daar ES, Haas DW, Li C, Shepherd BE. Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenetics and Genomics. 25: 450-61. PMID 26148204 DOI: 10.1097/Fpc.0000000000000156 |
0.332 |
|
| 2015 |
Lahiri CD, Tao S, Jiang Y, Sheth AN, Acosta EP, Marconi VC, Armstrong WS, Schinazi RF, Vunnava A, Sanford S, Ofotokun I. Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients. Aids (London, England). 29: 1113-5. PMID 25870991 DOI: 10.1097/Qad.0000000000000659 |
0.44 |
|
| 2015 |
Rizk ML, Du L, Bennetto-Hood C, Wenning L, Teppler H, Homony B, Graham B, Fry C, Nachman S, Wiznia A, Worrell C, Smith B, Acosta EP. Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age. Journal of Clinical Pharmacology. 55: 748-56. PMID 25753401 DOI: 10.1002/Jcph.493 |
0.373 |
|
| 2015 |
James SH, Larson KB, Acosta EP, Prichard MN. Helicase-primase as a target of new therapies for herpes simplex virus infections. Clinical Pharmacology and Therapeutics. 97: 66-78. PMID 25670384 DOI: 10.1002/Cpt.3 |
0.369 |
|
| 2015 |
Sutton AL, Acosta EP, Larson KB, Kerstner-Wood CD, Tita AT, Biggio JR. Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis. American Journal of Obstetrics and Gynecology. 212: 812.e1-6. PMID 25595580 DOI: 10.1016/J.Ajog.2015.01.015 |
0.364 |
|
| 2015 |
Viani R, Alvero C, Fenton T, Acosta E, Hazra R, Townley E, Palumbo P, Steimers D, Buchanan A, Vavro C, Wiznia A. Long-Term Safety and Efficacy of Dolutegravir in HIV Treatment-Experienced Adolescents Open Forum Infectious Diseases. 2. DOI: 10.1093/Ofid/Ofv133.343 |
0.355 |
|
| 2014 |
Larson KB, Wang K, Delille C, Otofokun I, Acosta EP. Pharmacokinetic enhancers in HIV therapeutics. Clinical Pharmacokinetics. 53: 865-72. PMID 25164142 DOI: 10.1007/S40262-014-0167-9 |
0.467 |
|
| 2014 |
Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M. Raltegravir pharmacokinetics in neonates following maternal dosing. Journal of Acquired Immune Deficiency Syndromes (1999). 67: 310-5. PMID 25162819 DOI: 10.1097/Qai.0000000000000316 |
0.389 |
|
| 2014 |
Kamal MA, Acosta EP, Kimberlin DW, Gibiansky L, Jester P, Niranjan V, Rath B, Clinch B, Sánchez PJ, Ampofo K, Whitley R, Rayner CR. The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach. Clinical Pharmacology and Therapeutics. 96: 380-9. PMID 24865390 DOI: 10.1038/Clpt.2014.120 |
0.33 |
|
| 2014 |
Haas DW, Kwara A, Richardson DM, Baker P, Papageorgiou I, Acosta EP, Morse GD, Court MH. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. The Journal of Antimicrobial Chemotherapy. 69: 2175-82. PMID 24729586 DOI: 10.1093/Jac/Dku110 |
0.42 |
|
| 2014 |
Delille CA, Pruett ST, Marconi VC, Lennox JL, Armstrong WS, Arrendale RF, Sheth AN, Easley KA, Acosta EP, Vunnava A, Ofotokun I. Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations. Journal of Clinical Pharmacology. 54: 1063-71. PMID 24691856 DOI: 10.1002/Jcph.298 |
0.417 |
|
| 2014 |
Wang K, D'Argenio DZ, Acosta EP, Sheth AN, Delille C, Lennox JL, Kerstner-Wood C, Ofotokun I. Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients. Clinical Pharmacokinetics. 53: 361-71. PMID 24311282 DOI: 10.1007/S40262-013-0122-1 |
0.451 |
|
| 2014 |
Acosta EP, Grigsby PL, Larson KB, James AM, Long MC, Duffy LB, Waites KB, Novy MJ. Transplacental transfer of Azithromycin and its use for eradicating intra-amniotic ureaplasma infection in a primate model. The Journal of Infectious Diseases. 209: 898-904. PMID 24179112 DOI: 10.1093/Infdis/Jit578 |
0.336 |
|
| 2014 |
Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A, et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 58: 413-22. PMID 24145879 DOI: 10.1093/Cid/Cit696 |
0.433 |
|
| 2014 |
Sonpavde G, Schnell FM, Wang CG, Mooney DJ, Naik G, Cantor A, Acosta EP, Eltoum I, Bolger G, DeShazo M, Saleh MN. Carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following chemotherapy and androgen pathway inhibitors. Journal of Clinical Oncology. 32: TPS5101-TPS5101. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps5101 |
0.325 |
|
| 2013 |
Larson KB, King JR, Acosta EP. Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics. Adolescent Health, Medicine and Therapeutics. 4: 79-87. PMID 24600298 DOI: 10.2147/Ahmt.S29462 |
0.421 |
|
| 2013 |
Johnson DH, Sutherland D, Acosta EP, Erdem H, Richardson D, Haas DW. Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study. Plos One. 8: e82672. PMID 24349334 DOI: 10.1371/Journal.Pone.0082672 |
0.322 |
|
| 2013 |
Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acosta EP, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DR. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. The Journal of Infectious Diseases. 208: 884-91. PMID 23801609 DOI: 10.1093/Infdis/Jit272 |
0.381 |
|
| 2013 |
Taiwo B, Acosta EP, Ryscavage P, Berzins B, Lu D, Lalezari J, Castro J, Adeyemi O, Kuritzkes DR, Eron JJ, Tsibris A, Swindells S. Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. Journal of Acquired Immune Deficiency Syndromes (1999). 64: 167-73. PMID 23797691 DOI: 10.1097/Qai.0B013E3182A03D95 |
0.401 |
|
| 2013 |
Vardhanabhuti S, Acosta EP, Ribaudo HJ, Severe P, Lalloo U, Kumarasamy N, Taulo F, Kabanda J, Oneko O, Ive P, Sambarey P, Chan ES, Hitti J, Hong F, McMahon D, et al. Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission. The Journal of Infectious Diseases. 208: 662-71. PMID 23687222 DOI: 10.1093/Infdis/Jit223 |
0.443 |
|
| 2013 |
Baheti G, King JR, Acosta EP, Fletcher CV. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults. Aids (London, England). 27: 221-5. PMID 23032419 DOI: 10.1097/Qad.0B013E32835A9A2D |
0.761 |
|
| 2013 |
Johnson DH, Gebretsadik T, Shintani A, Mayo G, Acosta EP, Stein CM, Haas DW. Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose. British Journal of Clinical Pharmacology. 75: 997-1006. PMID 22957905 DOI: 10.1111/J.1365-2125.2012.04454.X |
0.322 |
|
| 2013 |
Okulicz JF, Grandits GA, French JA, Perucca E, George JM, Landrum ML, Acosta EP, Birbeck GL. The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study. Epilepsy Research. 103: 245-53. PMID 22835761 DOI: 10.1016/J.Eplepsyres.2012.07.009 |
0.359 |
|
| 2012 |
Acosta EP, Limoli KL, Trinh L, Parkin NT, King JR, Weidler JM, Ofotokun I, Petropoulos CJ. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrobial Agents and Chemotherapy. 56: 5938-45. PMID 22964257 DOI: 10.1128/Aac.00691-12 |
0.418 |
|
| 2012 |
Sandkovsky U, Swindells S, Robbins BL, Nelson SR, Acosta EP, Fletcher CV. Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection. Aids (London, England). 26: 2257-9. PMID 22948265 DOI: 10.1097/Qad.0B013E328359A978 |
0.611 |
|
| 2012 |
Nikanjam M, Kabamba D, Cressey TR, Burger D, Aweeka FT, Acosta EP, Spector SA, Capparelli EV. Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrobial Agents and Chemotherapy. 56: 5374-80. PMID 22869579 DOI: 10.1128/Aac.00842-12 |
0.407 |
|
| 2012 |
Shytaj IL, Norelli S, Chirullo B, Della Corte A, Collins M, Yalley-Ogunro J, Greenhouse J, Iraci N, Acosta EP, Barreca ML, Lewis MG, Savarino A. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. Plos Pathogens. 8: e1002774. PMID 22737073 DOI: 10.1371/Journal.Ppat.1002774 |
0.357 |
|
| 2012 |
Sandkovsky U, Swindells S, Moore R, Acosta EP, Fletcher CV. Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection. Pharmacotherapy. 32: 142-7. PMID 22392423 DOI: 10.1002/Phar.1015 |
0.591 |
|
| 2011 |
Huang Y, Wu H, Holden-Wiltse J, Acosta EP. A DYNAMIC BAYESIAN NONLINEAR MIXED-EFFECTS MODEL OF HIV RESPONSE INCORPORATING MEDICATION ADHERENCE, DRUG RESISTANCE AND COVARIATES(). The Annals of Applied Statistics. 5: 551-577. PMID 23162677 DOI: 10.1214/10-Aoas376 |
0.402 |
|
| 2011 |
King J, McCall M, Cannella A, Markiewicz MA, James A, Hood CB, Acosta EP. A randomized crossover study to determine relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-dose combination tablet compared with a compounded oral liquid formulation derived from the tablet. Journal of Acquired Immune Deficiency Syndromes (1999). 56: e130-2. PMID 22046602 DOI: 10.1097/Qai.0B013E31820Eefbe |
0.719 |
|
| 2011 |
Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Eron JJ. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). Aids (London, England). 25: 2113-22. PMID 21857490 DOI: 10.1097/Qad.0B013E32834Bbaa9 |
0.359 |
|
| 2011 |
King JR, Yogev R, Jean-Philippe P, Graham B, Wiznia A, Britto P, Carey V, Hazra R, Acosta EP. Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients. Antimicrobial Agents and Chemotherapy. 55: 4290-4. PMID 21670182 DOI: 10.1128/Aac.01334-10 |
0.479 |
|
| 2011 |
Ofotokun I, Lennox JL, Eaton ME, Ritchie JC, Easley KA, Masalovich SE, Long MC, Acosta EP. Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure. Journal of Clinical Pharmacology. 51: 1539-48. PMID 21209245 DOI: 10.1177/0091270010385118 |
0.438 |
|
| 2010 |
Acosta EP, Kimberlin DW. Determination of appropriate dosing of influenza drugs in pediatric patients Clinical Pharmacology and Therapeutics. 88: 704-707. PMID 20881956 DOI: 10.1038/Clpt.2010.173 |
0.356 |
|
| 2010 |
Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, Ritchie MD, Zanger UM, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford D, Haas DW. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. The Journal of Infectious Diseases. 202: 717-22. PMID 20662624 DOI: 10.1086/655470 |
0.315 |
|
| 2010 |
Huang Y, Wu H, Acosta EP. Hierarchical Bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors. Biometrical Journal. Biometrische Zeitschrift. 52: 470-86. PMID 20661953 DOI: 10.1002/Bimj.200900173 |
0.425 |
|
| 2010 |
Acosta EP, Jester P, Gal P, Wimmer J, Wade J, Whitley RJ, Kimberlin DW. Oseltamivir dosing for influenza infection in premature neonates. The Journal of Infectious Diseases. 202: 563-6. PMID 20594104 DOI: 10.1086/654930 |
0.32 |
|
| 2010 |
McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, Maldarelli F. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 50: 912-9. PMID 20156060 DOI: 10.1086/650749 |
0.44 |
|
| 2010 |
Overton ET, Tschampa JM, Klebert M, Royal M, Rodriguez M, Spitz T, Kim G, Mondy KE, Acosta EP. The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy. Journal of Clinical Pharmacology. 50: 1050-5. PMID 20147613 DOI: 10.1177/0091270009357431 |
0.413 |
|
| 2010 |
Megazzini KM, Sinkala M, Vermund SH, Redden DT, Krebs DW, Acosta EP, Mwanza J, Goldenberg RL, Chintu N, Bulterys M, Stringer JS. A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia. Aids (London, England). 24: 447-55. PMID 19926959 DOI: 10.1097/Qad.0B013E328334B285 |
0.307 |
|
| 2009 |
Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). Hiv Clinical Trials. 10: 343-55. PMID 20133265 DOI: 10.1310/Hct1006-343 |
0.352 |
|
| 2009 |
Rathbun CR, Liedtke MD, Blevins SM, Harrison D, Lockhart SM, Salvaggio M, Acosta EP. Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir. Hiv Clinical Trials. 10: 328-36. PMID 19906626 DOI: 10.1310/Hct1005-328 |
0.324 |
|
| 2009 |
Redhage LA, Shintani A, Haas DW, Emeagwali N, Markovic M, Oboho I, Mwenya C, Erdem H, Acosta EP, Morrow JD, Hulgan T. Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults. Hiv Clinical Trials. 10: 181-92. PMID 19632957 DOI: 10.1310/Hct1003-181 |
0.375 |
|
| 2009 |
Bennetto-Hood C, Bryson YJ, Stek A, King JR, Mirochnick M, Acosta EP. Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. Hiv Clinical Trials. 10: 41-7. PMID 19362995 DOI: 10.1310/Hct1001-41 |
0.306 |
|
| 2009 |
Haas DW, Gebretsadik T, Mayo G, Menon UN, Acosta EP, Shintani A, Floyd M, Stein CM, Wilkinson GR. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. The Journal of Infectious Diseases. 199: 872-80. PMID 19239339 DOI: 10.1086/597125 |
0.395 |
|
| 2009 |
Haas DW, Koletar SL, Laughlin L, Kendall MA, Suckow C, Gerber JG, Zolopa AR, Bertz R, Child MJ, Hosey L, Alston-Smith B, Acosta EP. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. Journal of Acquired Immune Deficiency Syndromes (1999). 50: 290-3. PMID 19194314 DOI: 10.1097/Qai.0B013E318189A7Df |
0.441 |
|
| 2009 |
Long MC, King JR, Acosta EP. Pharmacologic aspects of new antiretroviral drugs. Current Hiv/Aids Reports. 6: 43-50. PMID 19149996 DOI: 10.1007/S11904-009-0007-Y |
0.379 |
|
| 2009 |
King JR, Acosta EP, Yogev R, Wiznia A, Kraimer J, Graham B, Carey V, Britto P, Jean-Philippe P, Moye J, Watson D. Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients. The Pediatric Infectious Disease Journal. 28: 159-61. PMID 19106779 DOI: 10.1097/Inf.0B013E3181861D8B |
0.404 |
|
| 2008 |
Long MC, King JR, Acosta EP. Pharmacologic aspects of new antiretroviral drugs. Current Infectious Disease Reports. 10: 522-9. PMID 18945395 DOI: 10.1007/S11908-008-0084-X |
0.379 |
|
| 2008 |
Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, Zhou Y, Pitt E, Anderson KS, Acosta EP, Siliciano RF. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nature Medicine. 14: 762-6. PMID 18552857 DOI: 10.1038/Nm1777 |
0.455 |
|
| 2008 |
Kilby JM, Lee HY, Hazelwood JD, Bansal A, Bucy RP, Saag MS, Shaw GM, Acosta EP, Johnson VA, Perelson AS, Goepfert PA. Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. Aids (London, England). 22: 957-62. PMID 18453855 DOI: 10.1097/Qad.0B013E3282Fbd1Da |
0.451 |
|
| 2008 |
Kimberlin DW, Acosta EP, Sánchez PJ, Sood S, Agrawal V, Homans J, Jacobs RF, Lang D, Romero JR, Griffin J, Cloud GA, Lakeman FD, Whitley RJ. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. The Journal of Infectious Diseases. 197: 836-45. PMID 18279073 DOI: 10.1086/528376 |
0.389 |
|
| 2008 |
Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA, Shikuma C, Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP, Gulick RM. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. The Journal of Infectious Diseases. 197: 867-70. PMID 18269317 DOI: 10.1086/528802 |
0.336 |
|
| 2008 |
Ofotokun I, Acosta EP, Lennox JL, Pan Y, Easley KA. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. Pharmacotherapy. 28: 74-81. PMID 18154477 DOI: 10.1592/Phco.28.1.74 |
0.402 |
|
| 2008 |
Gerber JG, Kitch DW, Fichtenbaum CJ, Zackin RA, Charles S, Hogg E, Acosta EP, Connick E, Wohl D, Kojic EM, Benson CA, Aberg JA. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. Journal of Acquired Immune Deficiency Syndromes (1999). 47: 459-66. PMID 17971707 DOI: 10.1097/Qai.0B013E31815Bace2 |
0.386 |
|
| 2008 |
King J, Acosta E. Pediatric clinical pharmacology and its implications for antiretroviral drug development Current Opinion in Hiv and Aids. 3: 272-276. DOI: 10.1097/Coh.0B013E3282F64530 |
0.397 |
|
| 2007 |
Moore JD, Acosta EP, Johnson VA, Bassett R, Eron JJ, Fischl MA, Long MC, Kuritzkes DR, Sommadossi JP. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. Antiviral Therapy. 12: 981-6. PMID 17926654 |
0.359 |
|
| 2007 |
Tremoulet AH, Capparelli EV, Patel P, Acosta EP, Luzuriaga K, Bryson Y, Wara D, Zorrilla C, Holland D, Mirochnick M. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrobial Agents and Chemotherapy. 51: 4297-302. PMID 17893155 DOI: 10.1128/Aac.00332-07 |
0.407 |
|
| 2007 |
Ofotokun I, Chuck SK, Binongo JN, Palau M, Lennox JL, Acosta EP. Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. Journal of Clinical Pharmacology. 47: 970-7. PMID 17615254 DOI: 10.1177/0091270007302564 |
0.351 |
|
| 2007 |
Acosta EP, Kendall MA, Gerber JG, Alston-Smith B, Koletar SL, Zolopa AR, Agarwala S, Child M, Bertz R, Hosey L, Haas DW. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrobial Agents and Chemotherapy. 51: 3104-10. PMID 17576825 DOI: 10.1128/Aac.00341-07 |
0.393 |
|
| 2007 |
Parks DA, Jennings HC, Taylor CW, Acosta EP. Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects. Aids (London, England). 21: 1373-5. PMID 17545719 DOI: 10.1097/Qad.0B013E328133F068 |
0.48 |
|
| 2007 |
Zorrilla CD, Van Dyke R, Bardeguez A, Acosta EP, Smith B, Hughes MD, Huang S, Watts DH, Heckman B, Jiménez E, McSherry G, Mofenson L. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. Antimicrobial Agents and Chemotherapy. 51: 2208-10. PMID 17420209 DOI: 10.1128/Aac.00871-06 |
0.337 |
|
| 2007 |
Acosta EP, Brundage RC, King JR, Sánchez PJ, Sood S, Agrawal V, Homans J, Jacobs RF, Lang D, Romero JR, Griffin J, Cloud G, Whitley R, Kimberlin DW. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clinical Pharmacology and Therapeutics. 81: 867-72. PMID 17392728 DOI: 10.1038/Sj.Clpt.6100150 |
0.315 |
|
| 2007 |
King JR, Kakuda TN, Paul S, Tse MM, Acosta EP, Becker SL. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers. Journal of Clinical Pharmacology. 47: 201-8. PMID 17244771 DOI: 10.1177/0091270006296763 |
0.422 |
|
| 2007 |
Kshirsagar SA, Blaschke TF, Sheiner LB, Krygowski M, Acosta EP, Verotta D. Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria. Journal of Pharmacokinetics and Pharmacodynamics. 34: 35-55. PMID 17004125 DOI: 10.1007/S10928-006-9032-2 |
0.37 |
|
| 2006 |
Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. Jama. 296: 769-81. PMID 16905783 DOI: 10.1001/Jama.296.7.769 |
0.46 |
|
| 2006 |
King JR, Acosta EP. Tipranavir: a novel nonpeptidic protease inhibitor of HIV. Clinical Pharmacokinetics. 45: 665-82. PMID 16802849 DOI: 10.2165/00003088-200645070-00003 |
0.452 |
|
| 2006 |
Wu H, Huang Y, Acosta EP, Park JG, Yu S, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS, Gerber JG. Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. Journal of Pharmacokinetics and Pharmacodynamics. 33: 399-419. PMID 16583266 DOI: 10.1007/S10928-006-9006-4 |
0.438 |
|
| 2006 |
Morse GD, Catanzaro LM, Acosta EP. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. The Lancet. Infectious Diseases. 6: 215-25. PMID 16554246 DOI: 10.1016/S1473-3099(06)70436-4 |
0.414 |
|
| 2006 |
Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, Parkin N, Deeks SG. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. Aids (London, England). 20: 223-31. PMID 16511415 DOI: 10.1097/01.Aids.0000199825.34241.49 |
0.312 |
|
| 2006 |
Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 42: 401-7. PMID 16392089 DOI: 10.1086/499364 |
0.577 |
|
| 2005 |
Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaudo H, Gulick RM. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Annals of Internal Medicine. 143: 714-21. PMID 16287792 DOI: 10.7326/0003-4819-143-10-200511150-00008 |
0.411 |
|
| 2005 |
Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta EP, Martinez A, Jiang H, Gulick RM. Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. Journal of Acquired Immune Deficiency Syndromes (1999). 40: 301-6. PMID 16249704 DOI: 10.1097/01.Qai.0000180078.53321.6A |
0.619 |
|
| 2005 |
King JR, Nachman S, Yogev R, Hodge J, Aldrovandi G, Hughes MD, Chen J, Wiznia A, Damle B, Acosta EP. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. The Pediatric Infectious Disease Journal. 24: 880-5. PMID 16220085 DOI: 10.1097/01.Inf.0000180508.21918.8A |
0.436 |
|
| 2005 |
Stringer JS, Sinkala M, Maclean CC, Levy J, Kankasa C, Degroot A, Stringer EM, Acosta EP, Goldenberg RL, Vermund SH. Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. Aids (London, England). 19: 1309-15. PMID 16052086 DOI: 10.1097/01.Aids.0000180102.88511.7D |
0.382 |
|
| 2005 |
Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R, Gatti G, Kurowski M, Perno CF, Peytavin G, Regazzi M, Back D. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antiviral Therapy. 10: 469-77. PMID 16038472 |
0.55 |
|
| 2005 |
Wu H, Huang Y, Acosta EP, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS, Gerber JG. Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. Journal of Acquired Immune Deficiency Syndromes (1999). 39: 272-83. PMID 15980686 DOI: 10.1097/01.Qai.0000165907.04710.Da |
0.461 |
|
| 2005 |
King JR, Gerber JG, Fletcher CV, Bushman L, Acosta EP. Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy. Aids (London, England). 19: 1059-63. PMID 15958837 DOI: 10.1097/01.Aids.0000174452.78497.54 |
0.54 |
|
| 2005 |
Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R, Gatti G, Kurowski M, Perno CF, Peytavin G, Regazzi M, Back D. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antiviral Therapy. 10: 375-92. PMID 15918329 |
0.558 |
|
| 2005 |
Kashuba AD, Tierney C, Downey GF, Acosta EP, Vergis EN, Klingman K, Mellors JW, Eshleman SH, Scott TR, Collier AC. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. Aids (London, England). 19: 145-52. PMID 15668539 DOI: 10.1097/00002030-200501280-00006 |
0.328 |
|
| 2004 |
King JR, Yogev R, Aldrovandi G, Chadwick E, Acosta EP. Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube. Hiv Clinical Trials. 5: 288-93. PMID 15562369 DOI: 10.1310/Grqx-761M-Dpb1-V9Cg |
0.411 |
|
| 2004 |
Acosta EP, Wu H, Hammer SM, Yu S, Kuritzkes DR, Walawander A, Eron JJ, Fichtenbaum CJ, Pettinelli C, Neath D, Ferguson E, Saah AJ, Gerber JG. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. Journal of Acquired Immune Deficiency Syndromes (1999). 37: 1358-66. PMID 15483465 DOI: 10.1097/00126334-200411010-00004 |
0.469 |
|
| 2004 |
Swanstrom R, Bosch RJ, Katzenstein D, Cheng H, Jiang H, Hellmann N, Haubrich R, Fiscus SA, Fletcher CV, Acosta EP, Gulick RM. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. The Journal of Infectious Diseases. 190: 886-93. PMID 15295692 DOI: 10.1086/422692 |
0.63 |
|
| 2004 |
Penzak SR, Acosta EP, Turner M, Tavel JA, Masur H. Antiretroviral drug content in products from developing countries. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 38: 1317-9. PMID 15127347 DOI: 10.1086/383575 |
0.303 |
|
| 2004 |
Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. The New England Journal of Medicine. 350: 1850-61. PMID 15115831 DOI: 10.1056/Nejmoa031772 |
0.445 |
|
| 2004 |
King JR, Wynn H, Brundage R, Acosta EP. Pharmacokinetic enhancement of protease inhibitor therapy. Clinical Pharmacokinetics. 43: 291-310. PMID 15080763 DOI: 10.2165/00003088-200443050-00003 |
0.453 |
|
| 2004 |
Stringer JS, Sinkala M, Goldenberg RL, Kumwenda R, Acosta EP, Aldrovandi GM, Stout JP, Vermund SH. Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings. Aids (London, England). 18: 939-43. PMID 15060442 DOI: 10.1097/00002030-200404090-00012 |
0.388 |
|
| 2004 |
Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. The Journal of Infectious Diseases. 189: 1176-84. PMID 15031785 DOI: 10.1086/382754 |
0.597 |
|
| 2004 |
Acosta EP, Bardeguez A, Zorrilla CD, Van Dyke R, Hughes MD, Huang S, Pompeo L, Stek AM, Pitt J, Watts DH, Smith E, Jiménez E, Mofenson L. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrobial Agents and Chemotherapy. 48: 430-6. PMID 14742191 DOI: 10.1128/Aac.48.2.430-436.2004 |
0.417 |
|
| 2004 |
Dubuisson JG, King JR, Stringer JS, Turner ML, Bennetto C, Acosta EP. Detection of nevirapine in plasma using thin-layer chromatography. Journal of Acquired Immune Deficiency Syndromes (1999). 35: 155-7. PMID 14722448 DOI: 10.1097/00126334-200402010-00009 |
0.374 |
|
| 2004 |
Bennetto CJ, King JR, Turner ML, Stringer JS, Acosta EP. Effects of concentration and temperature on the stability of nevirapine in whole blood and serum. Clinical Chemistry. 50: 209-11. PMID 14709651 DOI: 10.1373/Clinchem.2003.026492 |
0.398 |
|
| 2003 |
Stringer JS, Sinkala M, Goldenberg R, Vermund S, Acosta E. Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1. Lancet. 362: 667. PMID 12944077 DOI: 10.1016/S0140-6736(03)14172-4 |
0.364 |
|
| 2003 |
Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG, Acosta EP, Taylor KH, Carter J, Saag MS. Duration of highly active antiretroviral therapy regimens. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 37: 714-22. PMID 12942406 DOI: 10.1086/377271 |
0.407 |
|
| 2003 |
Stringer JS, Sinkala M, Chapman V, Acosta EP, Aldrovandi GM, Mudenda V, Stout JP, Goldenberg RL, Kumwenda R, Vermund SH. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. Aids (London, England). 17: 1659-65. PMID 12853748 DOI: 10.1097/00002030-200307250-00010 |
0.422 |
|
| 2003 |
Acosta EP, Balfour HH. Intermittent administration of high-dose stavudine to nucleoside-experienced individuals infected with HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999). 33: 343-8. PMID 12843745 DOI: 10.1097/00126334-200307010-00008 |
0.445 |
|
| 2003 |
Gerber JG, Acosta EP. Therapeutic drug monitoring in the treatment of HIV-infection Journal of Clinical Virology. 27: 117-128. PMID 12829033 DOI: 10.1016/S1386-6532(03)00033-7 |
0.443 |
|
| 2003 |
Stringer JS, Sinkala M, Stout JP, Goldenberg RL, Acosta EP, Chapman V, Kumwenda-Phiri R, Vermund SH. Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings. Journal of Acquired Immune Deficiency Syndromes (1999). 32: 506-13. PMID 12679702 DOI: 10.1097/00126334-200304150-00007 |
0.408 |
|
| 2003 |
King JR, Acosta EP, Chadwick E, Yogev R, Crain M, Pass R, Kimberlin DW, Sturdevant MS, Aldrovandi GM. Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients. The Pediatric Infectious Disease Journal. 22: 239-44. PMID 12634585 DOI: 10.1097/01.Inf.0000055093.42130.40 |
0.481 |
|
| 2003 |
Acosta EP, King JR. Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 36: 373-7. PMID 12539082 DOI: 10.1086/345993 |
0.41 |
|
| 2003 |
Turner ML, Reed-Walker K, King JR, Acosta EP. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 784: 331-41. PMID 12505781 DOI: 10.1016/S1570-0232(02)00822-X |
0.371 |
|
| 2002 |
King JR, Nachman S, Yogev R, Hodge J, Aldrovandi G, Damle B, Smith E, Wiznia A, Acosta EP. Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children. Antiviral Therapy. 7: 267-70. PMID 12553481 |
0.368 |
|
| 2002 |
King JR, Kimberlin DW, Aldrovandi GM, Acosta EP. Antiretroviral pharmacokinetics in the paediatric population: a review. Clinical Pharmacokinetics. 41: 1115-33. PMID 12405863 DOI: 10.2165/00003088-200241140-00001 |
0.417 |
|
| 2002 |
Chen RY, Westfall AO, Raper JL, Cloud GA, Chatham AK, Acosta EP, Pham SV, Tolson JM, Heudebert GR, Saag MS. Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice. Aids Research and Human Retroviruses. 18: 909-16. PMID 12230934 DOI: 10.1089/088922202760265588 |
0.309 |
|
| 2002 |
Acosta EP, Fletcher CV, Flexner C, Haas D, Hall S, Hamzeh F, Haubrich R, Kashuba A, Katzenstein D, Lawrence J, Lertora J, Gerber JG, Para M, Rosenkranz S, Sheiner L, et al. Position paper on therapeutic drug monitoring of antiretroviral agents Aids Research and Human Retroviruses. 18: 825-834. PMID 12201904 DOI: 10.1089/08892220260190290 |
0.46 |
|
| 2002 |
Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. The Journal of Infectious Diseases. 186: 626-33. PMID 12195349 DOI: 10.1086/342681 |
0.61 |
|
| 2002 |
Pereira AS, Smeaton LM, Gerber JG, Acosta EP, Snyder S, Fiscus SA, Tidwell RR, Gulick RM, Murphy RL, Eron JJ. The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850). The Journal of Infectious Diseases. 186: 198-204. PMID 12134255 DOI: 10.1086/341209 |
0.392 |
|
| 2002 |
Acosta EP. Pharmacokinetic enhancement of protease inhibitors Journal of Acquired Immune Deficiency Syndromes. 29. PMID 11832697 DOI: 10.1097/00126334-200202011-00003 |
0.436 |
|
| 2002 |
Grodesky M, Acosta EP, Fujita N, Mason S, Gerber JG. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations. Hiv Clinical Trials. 2: 193-9. PMID 11590527 DOI: 10.1310/Lj7M-82Qx-5Qjj-1R6R |
0.414 |
|
| 2002 |
Penzak SR, Acosta EP, Turner M, Edwards DJ, Hon YY, Desai HD, Jann MW. Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. The Journal of Clinical Pharmacology. 42: 1165-1170. DOI: 10.1177/009127002237991 |
0.409 |
|
| 2001 |
Acosta EP, Zorrilla C, Van Dyke R, Bardeguez A, Smith E, Hughes M, Huang S, Pitt J, Watts H, Mofenson L. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. Hiv Clinical Trials. 2: 460-5. PMID 11742433 DOI: 10.1310/Puy3-5Jwl-Fx2B-98Vu |
0.411 |
|
| 2001 |
Acosta EP, Balfour HH. Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics. Antimicrobial Agents and Chemotherapy. 45: 2771-4. PMID 11557467 DOI: 10.1128/Aac.45.10.2771-2774.2001 |
0.352 |
|
| 2001 |
Montaner J, Hill A, Acosta E. Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios. The Lancet. 357: 1438-1440. PMID 11356471 DOI: 10.1016/S0140-6736(00)04577-3 |
0.464 |
|
| 2001 |
Gulick RM, Smeaton LM, D’Aquila RT, Eron JJ, Currier JS, Gerber JG, Acosta E, Sommadossi J, Tung R, Snyder S, Kuritzkes DR, Murphy RL. Indinavir, Nevirapine, Stavudine, and Lamivudine for Human Immunodeficiency Virus–Infected, Amprenavir-Experienced Subjects: AIDS Clinical Trials Group Protocol 373 The Journal of Infectious Diseases. 183: 715-721. PMID 11181147 DOI: 10.1086/318820 |
0.43 |
|
| 2001 |
Kakuda TN, Page LM, Anderson PL, Henry K, Schacker TW, Rhame FS, Acosta EP, Brundage RC, Fletcher CV. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir Antimicrobial Agents and Chemotherapy. 45: 236-242. PMID 11120972 DOI: 10.1128/Aac.45.1.236-242.2001 |
0.594 |
|
| 2001 |
Kuritzkes DR, Bassett RL, Johnson VA, Marschner IC, Eron JJ, Sommadossi JP, Acosta EP, Murphy RL, Fife K, Wood K, Bell D, Martinez A, Pettinelli CB. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. Aids (London, England). 14: 1553-61. PMID 10983642 DOI: 10.1097/00002030-200007280-00011 |
0.343 |
|
| 2000 |
Zhou XJ, Havlir DV, Richman DD, Acosta EP, Hirsch M, Collier AC, Tebas P, Sommadossi JP. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. Aids (London, England). 14: 2869-76. PMID 11153668 DOI: 10.1097/00002030-200012220-00008 |
0.388 |
|
| 2000 |
Fletcher CV, Acosta EP, Cheng H, Haubrich R, Fischl M, Raasch R, Mills C, Hu XJ, Katzenstein D, Remmel RP, Gulick RM. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884 Aids. 14: 2495-2501. PMID 11101060 DOI: 10.1097/00002030-200011100-00011 |
0.646 |
|
| 2000 |
Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359 Journal of Infectious Diseases. 182: 1375-1384. PMID 11023461 DOI: 10.1086/315867 |
0.625 |
|
| 2000 |
Moore JD, Dezube BJ, Gill P, Zhou XJ, Acosta EP, Sommadossi JP. Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma. Cancer Chemotherapy and Pharmacology. 46: 173-9. PMID 11021733 DOI: 10.1007/S002800000149 |
0.351 |
|
| 2000 |
Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors Clinical Infectious Diseases. 30. PMID 10860900 DOI: 10.1086/313852 |
0.605 |
|
| 2000 |
Turner ML, Acosta EP. Long-Term Stability of Nelfinavir Mesylate in Human Plasma Clinical Chemistry. 46: 2019-2020. DOI: 10.1093/Clinchem/46.12.2019 |
0.399 |
|
| 1999 |
Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy. 19: 708-12. PMID 10391416 DOI: 10.1592/Phco.19.9.708.31544 |
0.549 |
|
| 1999 |
Fletcher CV, Kakuda TN, Page LM, Acosta EP, Brundage RC, Anderson PL, Henry K, Schacker T. Pharmacokinetic strategies for concentration-targeted therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV) Clinical Pharmacology and Therapeutics. 65: 161. DOI: 10.1016/S0009-9236(99)80174-X |
0.548 |
|
| 1998 |
Kakuda TN, Acosta EP, Fletcher CV. Potential confusion with antiretroviral drugs American Journal of Health-System Pharmacy. 55: 2639-2640. PMID 9872703 DOI: 10.1093/Ajhp/55.24.2639 |
0.548 |
|
| 1998 |
Fletcher CV, Acosta EP, Henry K, Page LM, Gross CR, Kawle SP, Remmel RP, Erice A, Balfour HH. Concentration-controlled zidovudine therapy. Clinical Pharmacology and Therapeutics. 64: 331-8. PMID 9757157 DOI: 10.1016/S0009-9236(98)90182-5 |
0.648 |
|
| 1997 |
Acosta EP, Henry K, Page LM, Erice A, Balfour HH, Fletcher CV. Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy. Pharmacotherapy. 17: 424-430. DOI: 10.1002/J.1875-9114.1997.Tb03052.X |
0.577 |
|
| 1996 |
Balfour HH, Fletcher CV, Erice A, Henry WK, Acosta EP, Smith SA, Holm MA, Boivin G, Shepp DH, Crumpacker CS, Eaton CA, Martin-Munley SS. Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Antimicrobial Agents and Chemotherapy. 40: 2721-6. PMID 9124829 DOI: 10.1128/Aac.40.12.2721 |
0.635 |
|
| 1996 |
Acosta EP, Page LM, Fletcher CV. Clinical pharmacokinetics of zidovudine. An update. Clinical Pharmacokinetics. 30: 251-62. PMID 8983858 DOI: 10.2165/00003088-199630040-00001 |
0.62 |
|
| 1996 |
Acosta EP, Schwebke K, Henry K, Fletcher CV. Disposition of zidovudine in obese pregnant women with human immunodeficiency virus type 1 infection. The Journal of Infectious Diseases. 174: 673. PMID 8769638 DOI: 10.1093/Infdis/174.3.673 |
0.518 |
|
| 1995 |
Acosta EP, Fletcher CV. Antiretroviral drug interactions. International Journal of Antimicrobial Agents. 5: 73-83. PMID 18611653 DOI: 10.1016/0924-8579(94)00063-Z |
0.61 |
|
| 1995 |
Schwebke K, Fletcher CV, Acosta EP, Henry K. Pentamidine concentrations in a mother with AIDS and in her neonate. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 20: 1569-70. PMID 7548518 DOI: 10.1093/Clinids/20.6.1569 |
0.533 |
|
| 1995 |
Acosta EP, Fletcher CV. Antiretroviral drug interactions International Journal of Antimicrobial Agents. 5: 73-83. DOI: 10.1016/0924-8579(94)00063-Z |
0.573 |
|
| 1994 |
Fletcher CV, Acosta EP, Strykowski JM. Gender differences in human pharmacokinetics and pharmacodynamics. The Journal of Adolescent Health : Official Publication of the Society For Adolescent Medicine. 15: 619-29. PMID 7696281 DOI: 10.1016/S1054-139X(94)90628-9 |
0.53 |
|
| 1994 |
Acosta EP, Fletcher CV. Agents for treating human immunodeficiency virus infection American Journal of Health-System Pharmacy. 51: 2251-2267. DOI: 10.1093/Ajhp/51.18.2251 |
0.607 |
|
| 1993 |
Fletcher CV, Acosta EP. Advances in pharmacotherapy: treatment of HIV infection Journal of Clinical Pharmacy and Therapeutics. 18: 375-388. DOI: 10.1111/J.1365-2710.1993.Tb00875.X |
0.639 |
|
| Show low-probability matches. |
